HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.

AuthorsMarko Lucijanic, Ruzica Lasan-Trcic, Rajko Kusec, Vlatko Pejsa, Tajana Stoos-Veic, Ozren Jaksic
JournalAnnals of hematology (Ann Hematol) Vol. 94 Issue 9 Pg. 1617-9 (Sep 2015) ISSN: 1432-0584 [Electronic] Germany
PMID26088813 (Publication Type: Case Reports, Letter)
Chemical References
  • Antimetabolites, Antineoplastic
  • Azacitidine
Topics
  • Antimetabolites, Antineoplastic (administration & dosage, adverse effects)
  • Azacitidine (administration & dosage, adverse effects)
  • Breast Neoplasms (drug therapy, genetics, pathology)
  • Chromosome Deletion
  • Chromosomes, Human, Pair 12 (genetics)
  • Chromosomes, Human, Pair 13 (genetics)
  • Drug Resistance, Neoplasm (drug effects, genetics)
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute (chemically induced, drug therapy, genetics, pathology)
  • Middle Aged
  • Myelodysplastic Syndromes (chemically induced, genetics, pathology)
  • Neoplasms, Second Primary (drug therapy, genetics, pathology)
  • Translocation, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: